Asymchem Laboratories (Tianjin) Co., Ltd. (6821.HK)
HKD 57.35
(4.08%)
HKD 57.35
(4.08%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4 Billion CNY | -17.59% |
| 2022 | 4.85 Billion CNY | 136.22% |
| 2021 | 2.05 Billion CNY | 40.26% |
| 2020 | 1.46 Billion CNY | 30.98% |
| 2019 | 1.11 Billion CNY | 31.2% |
| 2018 | 853.2 Million CNY | 15.88% |
| 2017 | 736.3 Million CNY | 29.34% |
| 2016 | 569.27 Million CNY | 42.13% |
| 2015 | 400.52 Million CNY | 28.47% |
| 2014 | 311.75 Million CNY | 28.18% |
| 2013 | 243.22 Million CNY | 23.99% |
| 2012 | 196.15 Million CNY | 4.07% |
| 2011 | 188.48 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 609.2 Million CNY | 11.08% |
| 2024 Q2 | 527.79 Million CNY | -13.36% |
| 2024 Q3 | 668.34 Million CNY | 26.63% |
| 2023 Q2 | 1.36 Billion CNY | 25.28% |
| 2023 FY | 4 Billion CNY | -17.59% |
| 2023 Q4 | 548.42 Million CNY | -45.29% |
| 2023 Q3 | 1 Billion CNY | -26.5% |
| 2023 Q1 | 1.08 Billion CNY | -8.69% |
| 2022 Q3 | 1.29 Billion CNY | -9.91% |
| 2022 FY | 4.85 Billion CNY | 136.22% |
| 2022 Q4 | 1.19 Billion CNY | -7.94% |
| 2022 Q2 | 1.43 Billion CNY | 54.11% |
| 2022 Q1 | 932.81 Million CNY | 25.51% |
| 2021 Q1 | 333.14 Million CNY | -27.17% |
| 2021 Q4 | 743.24 Million CNY | 42.06% |
| 2021 FY | 2.05 Billion CNY | 40.26% |
| 2021 Q3 | 523.19 Million CNY | 14.52% |
| 2021 Q2 | 456.86 Million CNY | 37.14% |
| 2020 Q1 | 226.79 Million CNY | -33.77% |
| 2020 Q2 | 388.27 Million CNY | 71.2% |
| 2020 FY | 1.46 Billion CNY | 30.98% |
| 2020 Q3 | 393.68 Million CNY | 1.39% |
| 2020 Q4 | 457.43 Million CNY | 16.19% |
| 2019 Q3 | 293.51 Million CNY | 7.66% |
| 2019 Q1 | 210.78 Million CNY | -28.76% |
| 2019 Q2 | 272.64 Million CNY | 29.35% |
| 2019 FY | 1.11 Billion CNY | 31.2% |
| 2019 Q4 | 342.45 Million CNY | 16.67% |
| 2018 Q1 | 181.08 Million CNY | -31.35% |
| 2018 FY | 853.2 Million CNY | 15.88% |
| 2018 Q4 | 295.89 Million CNY | 41.76% |
| 2018 Q3 | 208.72 Million CNY | 24.62% |
| 2018 Q2 | 167.49 Million CNY | -7.51% |
| 2017 Q2 | 145.89 Million CNY | 4.07% |
| 2017 FY | 736.3 Million CNY | 29.34% |
| 2017 Q4 | 263.76 Million CNY | 41.47% |
| 2017 Q3 | 186.44 Million CNY | 27.79% |
| 2017 Q1 | 140.19 Million CNY | -4.3% |
| 2016 Q1 | 97.99 Million CNY | -28.0% |
| 2016 FY | 569.27 Million CNY | 42.13% |
| 2016 Q4 | 146.49 Million CNY | -22.69% |
| 2016 Q3 | 189.5 Million CNY | 40.07% |
| 2016 Q2 | 135.28 Million CNY | 38.06% |
| 2015 Q3 | 80.9 Million CNY | 0.0% |
| 2015 Q4 | 136.1 Million CNY | 68.24% |
| 2015 FY | 400.52 Million CNY | 28.47% |
| 2014 FY | 311.75 Million CNY | 28.18% |
| 2013 FY | 243.22 Million CNY | 23.99% |
| 2012 FY | 196.15 Million CNY | 4.07% |
| 2011 FY | 188.48 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 392.81 Million HKD | -919.146% |
| CK Life Sciences Int'l., (Holdings) Inc. | 947.7 Million HKD | -322.429% |